Connor Clark & Lunn Investment Management Ltd. Acquires 55,567 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 7.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 780,933 shares of the biopharmaceutical company’s stock after acquiring an additional 55,567 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 1.34% of Vanda Pharmaceuticals worth $3,663,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $39,000. ORG Wealth Partners LLC acquired a new position in Vanda Pharmaceuticals during the third quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. increased its stake in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,374 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Vanda Pharmaceuticals in the second quarter worth $61,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Vanda Pharmaceuticals by 18.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Up 3.0 %

VNDA opened at $5.09 on Friday. The stock has a market capitalization of $296.80 million, a P/E ratio of -18.18 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 12 month low of $3.46 and a 12 month high of $6.75. The firm’s fifty day simple moving average is $4.80 and its 200 day simple moving average is $5.27.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VNDA. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Sunday, November 17th. They issued a “hold” rating for the company. Cantor Fitzgerald raised their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective for the company.

Insider Activity

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.